ArticleAntibiotics (Basel, Switzerland)2020
Tackling Intrinsic Antibiotic Resistance in Serratia Marcescens with A Combination of Ampicillin/Sulbactam and Phage SALSA.
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Phage-Antibiotic-Peptide Synergy Overcomes Biofilm-Mediated Multidrug Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026Review
- A Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-ResistantbioRxiv : the preprint server for biology · 2026Article
- A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Exploration of the feasibility of clinical application of phage treatment for multidrug-resistantEmerging microbes & infections · 2025Article
- Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample.BMC microbiology · 2025Article
- Combined Forces Against Bacteria: Phages and Antibiotics.Health science reports · 2025Article
- Isolation, characterization, and potential application of Acinetobacter baumannii phages against extensively drug-resistant strains.Virus genes · 2024Article
- Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.BMC infectious diseases · 2024Article
- Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.Pathogens and disease · 2024Article
- Benefits of Combined Phage-Antibiotic Therapy for the Control of Antibiotic-Resistant Bacteria: A Literature Review.Antibiotics (Basel, Switzerland) · 2022Review
- Synergy between Phage Sb-1 and Oxacillin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Phage Diversity for Research and Application.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the antibiotic crisis, bacteriophages (briefly phages) are increasingly considered as potential antimicrobial pillars for the treatment of infectious diseases. Apart from acquired drug resistance, treatment options are additionally hampered by intrinsic, chromosomal-encoded resistance. For instance, the chromosomal ampC gene encoding for the AmpC-type β-lactamases is typically present in a number of nosocomial pathogens, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.